Abstract:Disease overview Hodgkin lymphoma (HL) is an uncommon B‐cell lymphoid malignancy affecting 8,540 new patients annually and representing approximately 10% of all lymphomas in the United States. Diagnosis HL is composed of two distinct disease entities: classical HL and nodular lymphocyte predominant HL. Nodular sclerosis, mixed cellularity, lymphocyte depletion, and lymphocyte‐rich HL are subgroups of classical HL. Risk stratification An accurate assessment of the stage of disease in patients with HL is critical for the selection of the appropriate therapy. Prognostic models that identify patients at low or high risk for recurrence, as well as the response to therapy as determined by positron emission tomography (PET) scan, are used to optimize therapy. Risk‐Adapted Therapy Initial therapy for HL patients is based on the histology of the disease, the anatomical stage and the presence of poor prognostic features. Patients with early stage disease are typically treated with combined modality strategies utilizing abbreviated courses of combination chemotherapy followed by involved‐field radiation therapy, while those with advanced stage disease receive a longer course of chemotherapy often without radiation therapy. However, newer agents including brentuximab vedotin and anti‐PD‐1 antibodies are now being incorporated into frontline therapy. Management of relapsed/refractory disease High‐dose chemotherapy (HDCT) followed by an autologous stem cell transplant (ASCT) is the standard of care for most patients who relapse following initial therapy. For patients who fail HDCT with ASCT, brentuximab vedotin, PD‐1 blockade, non‐myeloablative allogeneic transplant or participation in a clinical trial should be considered. This article is protected by copyright. All rights reserved.

Novel therapy for Hodgkin lymphoma: reports in the 55th ASH annual meeting

Treatment and Radiotherapy Principle of Limited-Hodgkin Lymphoma:Report in the 54th ASH Annual Meeting

Research Progress in the Biology of Hodgkin's Lymphoma in the 54th ASH Annual Meeting

Hodgkin lymphoma: 2025 update on diagnosis, risk-stratification, and management

Hodgkin lymphoma: 2022 update on diagnosis, risk‐stratification, and management

Novel agents and regimens in relapsed or refractory peripheral T-cell lymphoma: latest updates from 2023 ASH annual meeting

[Lymphomas: A therapeutic update]

Integrating Novel Agents Into the Clinical Management of Classic Hodgkin Lymphoma

Optimal therapy of advanced Hodgkin' s lymphoma

Novel natural killer cell-based therapies for hematologic and solid malignancies: latest updates from ASCO 2024

Novel Targeted Agents in Hodgkin and Non-Hodgkin Lymphoma Therapy

Novel Cellular Immunotherapies for Hematological Malignancies: Recent Updates from the 2021 ASH Annual Meeting

Application of PET-CT in Hodgkin's lymphoma: a report from the 54th ASH annual meeting

Diagnostic and therapeutic developments in classical Hodgkin's lymphoma

Clinical Management of the Multiple Myeloma: Reports from the 56th American Society of Hematology Annual Meeting

Novel Therapies for Follicular Lymphoma and Other Indolent Non-Hodgkin Lymphomas

The evolving role of targeted drugs in the treatment of Hodgkin lymphoma

Novel targeted drugs for follicular and marginal zone lymphoma: a comprehensive review

Bispecific antibodies targeting CD20xCD3 in immunotherapy for adult B-cell lymphoma: insights from the 65th American Society of Hematology 2023 annual meeting

Research Progress of Hodgkin Lymphoma

Targeting indolent non-Hodgkin lymphoma